R. Molina

949 total citations · 1 hit paper
16 papers, 689 citations indexed

About

R. Molina is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, R. Molina has authored 16 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Pulmonary and Respiratory Medicine, 5 papers in Oncology and 4 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in R. Molina's work include Prostate Cancer Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). R. Molina is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (4 papers), Prostate Cancer Treatment and Research (4 papers) and Hepatocellular Carcinoma Treatment and Prognosis (3 papers). R. Molina collaborates with scholars based in Spain, United States and Austria. R. Molina's co-authors include Elżbieta Senkus, Andrea Nicolini, Michael J. Duffy, Fátima Cardoso, Nadia Harbeck, Xavier Filella, A M Ballesta, Aleix Cases, Judith Jo and Eric Mas and has published in prestigious journals such as European Journal of Cancer, Breast Cancer Research and Treatment and Tumor Biology.

In The Last Decade

R. Molina

15 papers receiving 670 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

2017 356 citations Michael J. Duffy, Nadia Harbeck et al. European Journal of Cancer profile →

Peers

Countries citing papers authored by R. Molina

Since Specialization

Citations

This map shows the geographic impact of R. Molina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Molina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Molina more than expected).

Fields of papers citing papers by R. Molina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Molina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Molina. The network helps show where R. Molina may publish in the future.

Co-authorship network of co-authors of R. Molina

This figure shows the co-authorship network connecting the top 25 collaborators of R. Molina. A scholar is included among the top collaborators of R. Molina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Molina. R. Molina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	4CPS-158 Prescribing trends of adalimumab and etanercept biosimilar drugs in a third level hospital 2020 ·Section 4: Clinical pharmacy services ·(unknown), (unknown), (unknown), R. Molina, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
2	Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM) breakdown → 2017 ·European Journal of Cancer ·Michael J. Duffy, Nadia Harbeck, (unknown), R. Molina, Andrea Nicolini, Elżbieta Senkus, Fátima Cardoso	356
3	Significance of serum CA125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up 2009 ·PubMed ·A. van Dalen, Judith Favier, (unknown), Alexander Burges, P Stieber, H.W.A. de Bruijn, Daniel Fink, Annamaria Ferrero, (unknown), A Harłozińska, Ch. Kainz, Janina Markowska, R. Molina, C. Sturgeon, A. Bowman, R. Einarsson, H. Goike	12
4	Cardiac safety and antitumor activity of doxorubicin and taxol followed by weekly taxol (AT&T) when herceptin is initiated with AT or with T alone in women with HER2-positive advanced breast cancer 2001 ·European Journal of Cancer ·Lorenzo Gianni, W. Eiermann, (unknown), Joan Albanell, R. Molina, (unknown), José Baselga	4
5	Evaluation of a Multivariate Prostate-Specific Antigen and Percentage of Free Prostate-Specific Antigen Logistic Regression Model in the Diagnosis of Prostate Cancer 1999 ·Tumor Biology ·Xavier Filella, (unknown), (unknown), R. Molina, Xavier Bosch‐Capblanch, Pablo Carretero, Antonio M. Ballesta	4
6	c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value 1998 ·Breast Cancer Research and Treatment ·R. Molina, Judith Jo, Xavier Filella, Gabriel Zanón, Jaume Pahisa, Montserrat Muñoz-Mateu, B. Farrús, (unknown), (unknown), Jordi Vilà, A M Ballesta	106
7	Free and Total PSA in the Diagnosis of Prostate Cancer 1997 ·Tumor Biology ·Xavier Filella, (unknown), R. Molina, (unknown), Pablo Carretero, Antonio M. Ballesta	10
8	Detection of occult liver metastases in colorectal cancer by measurement of biliary carcinoembryonic antigen. 1997 ·PubMed ·(unknown), Manuel Trías, R. Molina, Xavier Filella	8
9	Usefulness of Prostate-Specific Antigen Density as a Diagnostic Test of Prostate Cancer 1996 ·Tumor Biology ·Xavier Filella, (unknown), R. Molina, (unknown), Pablo Carretero, Antonio M. Ballesta	6
10	Multicentre Clinical Evaluation of the COBAS CORE CEA, CA 125 II and PSA Tumor Marker Assays 1996 ·The International Journal of Biological Markers ·Xavier Filella, Antonio M. Ballesta, Michelle E. Fox, Hugh Mitchell, R. Molina, (unknown), Helmut Thome	3
11	PP-4-23 CA 15-3, CEA and TPS for Monitoring metastatic breast cancer patients — a multicenter study 1996 ·European Journal of Cancer ·A. van Dalen, V. Barak, (unknown), María Gión, R. Molina, M. Namer, P Stieber, C. Sturgeon, R. Einarsson	1
12	Oncogenic proteins and prognostic correlations in breast cancer. 1994 ·PubMed ·R. Molina, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), B. Ojeda, (unknown), (unknown)	1
13	CEA as a prognostic factor in colorectal cancer. 1994 ·PubMed ·Xavier Filella, R. Molina, J.M. Piqué, J.J. Grau, J.C. García-Valdecasas, Albert Biete, (unknown), E. Astudillo, J.M. Bordas, Elı́as Campo	20
14	Tumor Markers in Chronic Renal Failure and Hemodialysis Patients 1991 ·The Nephron journals/Nephron journals ·Aleix Cases, Xavier Filella, R. Molina, A M Ballesta, José López‐Pedret, (unknown)	60
15	Serum Phosphohexose Isomerase Activities in Patients with Colorectal Cancer 1991 ·Tumor Biology ·Xavier Filella, R. Molina, (unknown), Eric Mas, A M Ballesta	53
16	Tumor Markers in Patients with Chronic Renal Failure 1990 ·The International Journal of Biological Markers ·Xavier Filella, Aleix Cases, R. Molina, Judith Jo, José Luis Bedini, L Revert, Antonio M. Ballesta	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact